Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pain Therapeutics and King Pharmaceuticals have initiated a phase I clinical trial to evaluate the effects of PTI-202 in humans. PTI-202 is a new drug candidate in the companies' collaboration to develop abuse-resistant opioid painkillers, a new category of drugs intended to prevent prescription drug abuse.
Subscribe to our email newsletter
PTI-202 is the second such drug to enter clinical development under the collaboration. The first drug to be developed was Remoxy, an abuse-resistant oxycodone which is currently in phase III trials.
Under the collaboration agreement, which was announced in November 2005, the companies agreed to co-develop and commercialize a total of four long-acting, abuse-resistant opioid painkillers.
Pain Therapeutics recently submitted an investigational new drug application (IND) to the FDA for PTI-202. FDA acceptance of this IND triggered the payment of a $5 million cash milestone from King to Pain Therapeutics.